Physiomics Regulatory News (PYC)

23 January 2024

Physiomics plc

("Physiomics" or "the Company")

IMC Presentation on Board Changes

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, will provide a brief update on the Board changes via Investor Meet Company on 29 January 2024 at 1:00 pm GMT. During this presentation, Jim Millen CEO and Peter Sargent would be happy to take questions relating to the changes announced yesterday. 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00 am GMT the working day before the meeting or at any time during the live presentation. 

Investors can sign up to Investor Meet Company for free and add to meet Physiomics plc via: https://www.investormeetcompany.com/physiomics-plc/register-investor. Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.

Enquiries:

Physiomics plc

Dr Jim Millen, Non-Executive Chairman, +44 (0)1865 784 980

Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour? technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.